If the BCL-3/β-catenin interaction could be mapped and disrupted, this may be an effective therapeutic approach for targeting CSC plasticity in CRC and may add to the current arsenal of Wnt-related inhibitors currently under development (Katoh, 2017). Here, BCL3 is linked to colorectal carcinoma.